Drugs / L-leucyl-L-leucine Methyl Ester
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00429416 | Mar 2004 → Dec 2008 | hematopoietic and lymphoid cell neoplasm | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00429039 | Sep 2000 → Oct 2007 | disease related to hematopoietic stem cell transplant | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | L-leucyl-L-leucine methyl ester | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00429039 ↗ |
| Known as | LLME | “The purpose of this study is to determine if pre-treating donor lymphocytes with an investigational drug known as L-leucyl-L-leucine methyl ester (LLME, prior to donor...” NCT00429039 ↗ |